Ciraparantag is in clinical development as a reversal agent for various anticoagulants including non-vitamin K oral anticoagulants (NOACs). Ciraparantag was previously shown to reverse the anticoagulant effects of edoxaban and enoxaparin, as measured by whole blood clotting time (WBCT).
Register to gain access to gated resources.
Thank you for registering!
You may now view the resource below.
In this eBook, we navigate the landscape of biomarker discovery through genomic profiling, exploring technologies, methods, and applications. We hope this collection of articles creates an appreciation for the wide scope of using sequencing assays for biomarker discovery, drug development, and beyond.
The diagnosis and treatment of human diseases and the development of new drugs increasingly rely on our ability to determine patient genotypes using accurate and sensitive pharmacogenomic tests. Many PCR and next-generation sequencing (NGS) based assay platforms are currently available.
However, the type of DNA sequence variants, the number of targets, and the sensitivity requirements are highly diverse in different studies. Here Dr. Peter Zhang describes the design, performance, and regulatory considerations of several assay platforms that are accurate, high throughput, cost-effective and customizable. These platforms provide high-quality pharmacogenomic data ideally suited to meet the needs of individual studies.
Performing robust exploratory tests upfront can save time and money later on in the process. This infographic outlines the top reasons for why clients are encouraged to consider a comprehensive exploratory toxicology program and how it can provide success in GLP studies.